About

Azevan Pharmaceuticals is a clinical stage, small molecule drug development company developing novel therapeutics to treat stress-related CNS disorders and neurodegenerative conditions. The Company’s first clinical compounds selectively block the effects of arginine vasopressin, a peptide neurohormone involved in the pathophysiology of multiple disorders, including neuropsychiatric symptoms in neurodegenerative diseases, Intermittent Explosive Disorder, and PTSD.  Vasopressin also is a key early signal in the neurological damage seen in traumatic brain injury and stroke.  Vasopressin 1a receptor antagonists represent a novel mechanism of action for addressing these indications.

The Company completed two Phase II clinical trials in adults with its lead compound, SRX246, for the treatment of Intermittent Explosive Disorder and for the treatment of irritability of Huntington’s Disease Patients (the STAIR trial). The primary endpoints and exploratory goals of both trials were achieved.  An additional Phase II clinical trial is in progress for the treatment of PTSD.